COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

A Study of the Absorption of GT267-004 in Patients With Clostridium Difficile-Associated Diarrhea

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00382304
Recruitment Status : Completed
First Posted : September 29, 2006
Last Update Posted : March 19, 2015
Information provided by:

Brief Summary:
Approximately 24 patients will be entered into this study taking place in Canada. The aim of this study is to determine if an investigational drug is absorbed (taken up) in patients with C. difficile-associated diarrhea (CDAD). The investigational drug will be given in addition to current standard antibiotic treatment so that all patients will receive active medication. All study related care is provided including doctor visits, physical exams, laboratory tests, and study medication. The total length of participation is approximately 7 days.

Condition or disease Intervention/treatment Phase
Pseudomembranous Colitis Clostridium Difficile Diarrhea Antibiotic-Associated Diarrhea Drug: tolevamer potassium-sodium (GT267-004) Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 24 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Study of the Pharmacokinetics of GT267-004 in Patients With Clostridium Difficile-Associated Diarrhea
Study Start Date : September 2006
Actual Study Completion Date : September 2007

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Diarrhea Potassium

Primary Outcome Measures :
  1. The extent of GT267-004 absorption as measured in the blood and urine by pharmacokinetic analysis

Secondary Outcome Measures :
  1. Safety as measured by physical examinations (including vital signs), adverse events and changes in safety laboratory values

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 18 years of age or older
  • The presence of CDAD at the time of enrollment with no other likely etiology for the diarrhea

Exclusion Criteria:

  • > 72 hours of treatment with metronidazole, vancomycin, or other antibacterial therapy specifically targeting the current acute episode of CDAD
  • Patient not considered sufficiently stable clinically to complete the study period

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00382304

Layout table for location information
Canada, Alberta
Edmonton, Alberta, Canada, T6G 2B7
Canada, British Columbia
Nanaimo, British Columbia, Canada, V9S 2B7
Vancouver, British Columbia, Canada, V3Z 1M9
Canada, Ontario
Ottowa, Ontario, Canada, K1H 8L6
Richmond Hill, Ontario, Canada, L4C 4Z3
Canada, Quebec
Montreal, Quebec, Canada, H3T 1E2
Rimouski, Quebec, Canada, G5L 5T1
Sherbrooke, Quebec, Canada, J1H 5N4
Sponsors and Collaborators
Genzyme, a Sanofi Company
Layout table for investigator information
Study Director: Medical Monitor Genzyme, a Sanofi Company

Layout table for additonal information
Responsible Party: Medical Monitor, Genzyme Corporation Identifier: NCT00382304    
Other Study ID Numbers: TOL26700606
First Posted: September 29, 2006    Key Record Dates
Last Update Posted: March 19, 2015
Last Verified: March 2015
Keywords provided by Sanofi:
Clostridium difficile-associated diarrhea
C. difficile
Clostridium difficile
Clostridium difficile Disease
Clostridium Enterocolitis
Antibiotic-Associated Colitis
Infectious diarrhea
Additional relevant MeSH terms:
Layout table for MeSH terms
Clostridium Infections
Enterocolitis, Pseudomembranous
Gastrointestinal Diseases
Digestive System Diseases
Colonic Diseases
Intestinal Diseases
Signs and Symptoms, Digestive
Signs and Symptoms
Gram-Positive Bacterial Infections
Bacterial Infections